The Prevalence of Activities of Daily Living Impairment in Patients With Heart Failure: A Systematic Review and Meta-Analysis

Objectives: The prevalence of activities of daily living (ADL) in patients with heart failure (HF) reported in current studies were inconsistent, ranging from 11.1 to 70.5%. The purpose of this study is to quantify the prevalence of ADL impairment in HF patients.

Methods: PubMed, Embase, Cochrane, CINAHL, CNKI, SinoMed, VIP, and Wanfang databases were systematically searched for relevant studies (up to March 2, 2022). Cross-sectional, case-control, or cohort studies with detailed descriptions of overall ADL impairment in HF were included. Stata 16.0 was used for statistical analysis. Fixed-effect or random-effect model was adopted according to heterogeneity which was evaluated by Cochran’s Q and I² values. Sensitivity analysis, subgroup analysis, and meta-regression were performed to investigate the sources of heterogeneity.

Results: A total of 12 studies with 15,795 HF patients were included in the meta-analysis, and the pooled prevalence of ADL impairment in patients with HF was 38.8% (95%CI: 28.2–49.3%; I² = 99.5%, P < 0.001). No possible sources of heterogeneity were found in subgroup analysis and meta-regression. Funnel plots and Egger’s test showed no publication bias (P = 0.595).

Conclusion: The prevalence of ADL impairment is relatively high in HF patients. Differences in the prevalence of ADL impairment in patients with HF may be influenced by country, region, and assessment time. We suggest that more researchers could focus on the changes of ADL impairment in HF patients during different disease periods in different regions and countries.

Introduction

Heart failure (HF) is a complex clinical syndrome characterized by deterioration of the heart and other systems such as the kidneys, liver, lungs, and muscles. It is estimated that 64.3 million people worldwide suffer from HF (1). The HF prevalence rises with age (2). More than 75% of hospitalization related to HF occurred in those aged 65 and older (3). The main clinical features of HF are fatigue, dyspnea, lower extremity edema, cough, precordial pain, dizziness, and palpitations. In the elderly, dyspnea and fatigue are prominent, which may lead to exercise intolerance and eventually to dependence on activities of daily living (ADL) (4, 5). In addition, HF is known to alter the function of skeletal muscle contraction units. Individuals with this chronic disease typically suffer from muscle weakness, which reduces their level of physical activity and their ability to maintain balance (6), leading to the patient’s inability to perform ADL independently (such as transferring, bathing, and toileting). As one of the most fundamental ability, ADL refers to the repetitive primary acts that people must accomplish in their daily life in order to meet their basic needs. It is a measurement tool for body objective condition, as well as an indication of health. ADL ability in HF patients is closely related to their prognosis. A study showed that patients with ADL impairment had an approximately threefold increase in 3-month readmission rates compared to patients without ADL impairment (7). Another study showed that ADL ability was an independent predictor of all-cause mortality in patients with HF (8). Physical limitations and loss of independence can complicate patients’ care and reduce patients’ quality of life (9). Therefore, it is crucial to adopt reasonable interventions to improve the ADL ability of HF patients.

To allow a more rational allocation of medical resources, the prevalence of ADL impairment among patients with HF must be identified first. However, currently, investigations on this topic give a wide range of results. In a study from America (US), the ADL impairment prevalence was 11.1% (10). One study from Europe (Poland) showed that the prevalence of ADL impairment was 26.3% (11). However, ADL impairment prevalence in an Asia (Japan) study was 70.5% (12). Those showed great differences between different regions and countries, and no systematic review and meta-analysis has been found. Hence, the purpose of this study is to quantify the prevalence of ADL impairment in patients with HF, so as to provide a basis for medical decision making in the management of HF patients.

Methods

This systematic review and meta-analysis was based on the preferred report items in the Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA 2020) guidelines.

Search Strategy

We searched four English databases (PubMed, Embase, Cochrane and CINAHL) and four Chinese databases (CNKI, Wanfang, VIP and SinoMed) for studies related to ADL impairment in patients with HF (from inception to March 2, 2022). We used the following search terms, adapted for each database when appropriate: ADL (“activities of daily living” or “ADL” or “Daily Living Activities” or “Chronic Limitation of Activity” or “ADL disability”) and HF (“heart failure” or “cardiac failure” or “cardiac dysfunction” or “cardiac insufficiency” or “Myocardial failure” or “Heart Decompensation” or “Congestive Heart Failure”) (the full list of search terms is provided in Supplementary File 1). We also reviewed the list of references in the included studies to obtain additional studies.

Inclusion/Exclusion Criteria

Inclusion criteria were: (1) Patients were diagnosed with HF; (2) The study included a detailed description of the assessment scale of ADL; (3) Complete baseline data of the total prevalence of ADL impairment was provided; (4) The study design was cross-sectional, case-control, or cohort; and (5) Research published in English or Chinese.

Exclusion criteria were: (1) meeting abstract, case report, review, meta-analysis, letter, pilot study or qualitative study; or (2) duplicate studies and/or data (When there are different studies in the same unit and the same sample, the most recent one is selected).

Two reviewers screened the literature separately according to the inclusion and exclusion criteria, and a third reviewer made a judgment if there were conflicts.

Data Extraction and Quality Assessment

Two investigators retrieved data from eligible studies independently, while a third investigator double-checked for accuracy. Data extracted included the first author, publication time, country, design, sample size, sex, age, type of patient, NYHA class III-V, LVEF, assessment scale, assessment time (Sources), and ADL impairment (cut-off, prevalence).

Quality of the included studies was evaluated using the modified Newcastle-Ottawa Scale (M-NOS) (12). There are 5 items, with 1 point given for each “Yes” answer and 0 point given for each “No” answer. The overall score runs from 0 and 5, with higher scores signifying higher quality. In this study, ≥ 3 was defined as low-risk bias and < 3 as high-risk bias.

Data Analysis

For statistical analysis, Stata 16.0 was employed. To examine heterogeneity, Cochran’s chi-square test (Cochran’s Q-value) and I²-value were used, with P < 0.05 or I² > 50% indicating significant heterogeneity between studies. Fixed-effect model was performed to calculate the pooled prevalence of ADL impairment in patients with HF when there was no significant heterogeneity, and random-effect model was used otherwise. Subgroup analysis, sensitivity analysis and meta-regression analysis were undertaken to identify the sources of heterogeneity. Funnel plots and Egger’s test were conducted to evaluate publication bias.

Results

Study Selection

A total of 12 studies were included in this systematic review and meta-analysis, involving 15,795 patients with HF. Sample size of the included studies ranged from 180 to 4,735. Details were showed in Figure 1.

FIGURE 1

Figure 1. Flow-chart illustrating the article search process.

Basic Information of the Included Studies

In this review, 5 studies were occurred in America (10, 13–16), 4 in Asia (7, 8, 12, 17) and 3 in Europe (11, 18, 19). The prevalence of ADL impairment in HF patients ranged from 11.1 to 70.5%. All studies received ≥ 3 points for quality measured by M-NOS (Tables 1A,B provides more information).

TABLE 1A

Table 1A. Characteristics of the included 12 studies.

TABLE 1B

Table 1B. ADL-related characteristics of the 12 included studies.

Pooled Prevalence of Activities of Daily Living Impairment in Patients With Heart Failure

A total of 12 studies were included in the meta-analysis. The pooled prevalence of ADL impairment was 38.8% (95%CI: 28.2–49.3%; I² = 99.5%, P < 0.001) (Figure 2).

FIGURE 2

Figure 2. Forest plot of eligible studies. Weights are from random-effects model.

Subgroup Analysis

Subgroup analysis showed that the pooled prevalence of ADL impairment in Asian, Europe and America regions was 50.3% (95%CI: 33.2–67.3%), 38.3% (95%CI: 21.4–55.2%), and 30.0% (95%CI: 15.7–44.1%) (Q = 3.25, P = 0.197). In the subgroup analysis of assessment scale, the prevalence was 49.0% (95%CI: 23.1–75.0%) by using BI, 32.1% (95%CI: 15.1–49.2%) by use other scale, and 35.2% (95%CI: 15.4–55.1%) by using KI (Q = 1.17, P = 0.556). The prevalence of was 66.2% (95%CI: 58.7–73.6%) on admission. When discharged from the hospital, the prevalence was 33.8% (95%CI: 19.1–48.5%). When measured in the out-of-hospital setting, such as in a community setting or prior to hospital admission, the prevalence was 33.0% (95%CI: 23.6–42.5%) (Q = 35.07, P < 0.001). In the assessment method subgroup analysis, the prevalence was 55.8% (95%CI: 27.0–84.6%) when the assessment was made by physical therapist, higher than 35.4% (95%CI: 23.9–46.7%) by self-report (Q = 1.66, P = 0.197). However, none of the subgroups might be a source of heterogeneity (Table 2).

TABLE 2

Table 2. Subgroup analysis of the pooled prevalence.

Meta-Regression Analysis

Meta-regression was performed on region, country, assessment scale, assessment time, method of assessment, sample size, study design, quality score, and publication time. The result indicated that assessment time accounted for 25.64% of the overall heterogeneity (B = -0.1450, P = 0.055) (Table 3).

TABLE 3

Table 3. Meta-regression analyses of the effects of potential moderators.

Sensitivity Analysis and Publication Bias

Sensitivity analysis revealed no outlier studies that might significantly alter the primary results (Figure 3). Although the funnel plot showed slight asymmetry (Figure 4A), Egger’s test did not support publication bias (t = 0.55, P = 0.595) (Figure 4B).

FIGURE 3

Figure 3. Sensitivity analysis estimating heterogeneity.

FIGURE 4

Figure 4. (A) Funnel plots of eligible studies showed slight asymmetry. (B) Egger’s test showed no publication bias.

Discussion

This systematic review and meta-analysis included 12 studies with a total sample size of 15,795 HF patients. The pooled results showed that 38.8% of HF patients suffer from ADL impairment. As far as we know, this meta-analysis is the first to quantitative the prevalence of ADL impairment in patients with HF worldwide.

The prevalence of ADL impairment in HF patients had a significant difference between countries (P = 0.001). The prevalence of ADL impairment in Asian was 50.3%, which was the highest among the three regions. In our review, the highest prevalence of ADL impairment in Japanese HF patients was 58.2%. Firstly, Japan is the country with the fastest aging population in the world. The number of HF patients in Japan, especially the elderly, is increasing rapidly (20). Secondly, this may be attributed to cultural differences (21). Many Asians have followed a culture of stoicism, especially in Japan. Patients tend to conceal their distressing symptoms in Asian cultures. Thirdly, the disparities in medical systems between countries also may explain the different prevalence of ADL impairment. Some reviews indicated that patients with HF in developing countries such as the Philippines and Vietnam receive lower-than-recommended levels of pharmacological therapy. They may experience more severe signs or symptoms than patients in developed countries (22, 23). As a cost-effective medical intervention, the variation in cardiac rehabilitation levels may also result in the disparity in the frequency of ADL impairment between different countries (24). Cardiac rehabilitation has been shown in a rising number of studies to enhance physical function and the ability to conduct everyday tasks in HF patients (25, 26). It is a pity that cardiac rehabilitation is available in only 17% of countries in Southeast Asia (27). The participation rate of cardiac rehabilitation remains low in developing countries, which may be related to the awareness of cardiac rehabilitation among patients and doctors, patients’ economic level, health insurance coverage, and the distance between patients’ residence and rehabilitation centers (28, 29).

The prevalence of ADL impairment in America and Europe regions was 30.0 and 38.3%. In Western cultures, patients are more likely to maintain a positive attitude toward the act of seeking medical care (30). Patients with HF in developed countries have nationalized health care and easy access to cardiologists. A global cross-sectional survey showed that cardiac rehabilitation services are available in 80.7% of European countries and 70.0% of American countries. All of the reasons above may explain the differences in ADL impairment between countries. But this review lack of enough studies to support the effect of the level of cardiac rehabilitation development on ADL impairment in HF patients. Thus, we suggest that more nations with insufficient levels of cardiac rehabilitation improve ADL in HF patients through cardiac rehabilitation.

Significant differences in the prevalence of ADL impairment may be related to assessment time. The highest prevalence of impaired ADL in HF patients was at admission (66.2%), followed by discharge (33.8%) and lowest in the out-of-hospital setting (33.0%). The higher ADL impairment prevalence in patients with HF in the acute setting (e.g., on admission) is reasonable. It can be explained by the presence of dyspnea, chest pain, and edema in the decompensated phase of HF patients (5). The HF symptoms described above objectively limit the ability of HF patients to perform daily activities. Some patients yield to avoid suffering the painful experience of HF symptoms and develop a fear of daily activities, which subjectively leads to impaired ADL. The prevalence at discharge (33.8%) was lower than that on admission (66.2%). After a series of medications, care and cardiac rehabilitation during hospitalization, it is reasonable for HF patients to have some recovery in their ability to perform daily living compared to the time of admission (26). B-type natriuretic peptide (BNP) is a cardiac hormone produced and secreted by the heart. Plasma BNP levels increase in proportion to the severity of heart failure and they decrease as treatment improves the patient’s condition (31). As changes in BNP level reflect hemodynamic deterioration/improvement, BNP reduction during hospitalization has the potential to add ADL improvement (32). The prevalence in out-of-hospital setting (such as community settings or prior to hospitalization) was 33.0%, lower than at admission or at discharge. Currently, impaired ADL in the out-of-hospital setting have received little attention. But still, we may not ignore the huge number of HF patients in the community. After all, hospitalized HF patients only account for about one-third of the total number of HF patients (33). Therefore, ADL impairment in HF patients should be taken into consideration by community health workers. Meanwhile, there are few longitudinal studies on ADL impairment in HF patients with different disease periods. We recommend that future studies focus on changes in ADL ability in patients with HF, so that appropriate interventions can be developed accordingly to enhance ADL ability.

However, the present study also has the following limitations. First, more than half of the included studies were conducted in Europe and the US, and for some reason there is a lack of relevant studies on ADL impairment in HF patients in other countries. This made the consult potentially unrepresentative on global level. Considering the imbalance of health care resources in different regions, we suggest that more studies should be conducted in different regions to understand the overall situation. Second, due to limited data from the original study, quantitative assessment of ADL impairment was lacking, as well as subgroup analysis of some influencing factors associated with ADL impairment, such as LVEF, BMI, and age, was not performed. It is expected that future studies will provide more original data to explore the sources of inter-study heterogeneity from the above perspectives. Last, the assessment tool of ADL included in this review were based on subjective feedback of the patients, which may not be objective enough. We expect that future studies will use more objective tools to evaluate ADLs (e.g., accelerometers).

Conclusion

The prevalence of ADL impairment in HF patients was 38.8%. Additionally, differences in the prevalence of ADL impairment in patients with HF may stem from country, region, and assessment time. We suggest that more researchers focus on the changes of ADL impairment in HF patients during different disease periods in different regions and countries.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Author Contributions

JL and YZ searched and checked the databases according to the inclusion and exclusion criteria, extracted the data, and assessed their quality. JL analyzed the data and wrote the draft of the manuscript. RY and MW gave advice on meta-analysis methodology and revised the manuscript. XS was the guarantors of this work and had full access to all the data in the study and took responsibility for its integrity and the accuracy of the data analysis. All authors contributed to reviewing read and approved the final manuscript.

Funding

This work was supported by grants from Geriatric Health Research Project of Jiangsu Province (No. LK2021018) to XS.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

We thank Yixiu Liu for her great assistance in translation.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.952926/full#supplementary-material

References

1. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. (2020) 22:1342–56. doi: 10.1002/ejhf.1858

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. (2017) 3:7–11. doi: 10.15420/cfr.2016:25:2

CrossRef Full Text | Google Scholar

3. Kumar K, Afonso L. Cardiovascular risk prediction in the elderly. J Geriatr Cardiol. (2019) 16:414–20. doi: 10.11909/j.issn.1671-5411.2019.05.010

PubMed Abstract | CrossRef Full Text | Google Scholar

4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2021) 42:3599–726. doi: 10.1093/eurheartj/ehab368

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Xavier SDO, Ferretti-Rebustini REDL. Clinical characteristics of heart failure associated with functional dependence at admission in hospitalized elderly. Rev Lat Am Enferm. (2019) 27:e3137. doi: 10.1590/1518-8345.2869-3137

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Miller MS, Vanburen P, Lewinter MM, Lecker SH, Selby DE, Palmer BM, et al. Mechanisms underlying skeletal muscle weakness in human heart failure: alterations in single fiber myosin protein content and function. Circ Heart Fail. (2009) 2:700–6. doi: 10.1161/CIRCHEARTFAILURE.109.876433

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Van Nguyen T, Dang HT, Burns MJ, Dao HH, Nguyen TN. Impairment in activities of daily living and readmission in older patients with heart failure: a cohort study. BMJ Open. (2021) 11:e44416. doi: 10.1136/bmjopen-2020-044416

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Katano S, Yano T, Ohori K, Kouzu H, Nagaoka R, Honma S, et al. Barthel index score predicts mortality in elderly heart failure-a goal of comprehensive cardiac rehabilitation. Circ J. (2021) 86:70–8. doi: 10.1253/circj.CJ-21-0584

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Dunlay SM, Manemann SM, Chamberlain AM, Cheville AL, Jiang R, Weston SA, et al. Activities of daily living and outcomes in heart failure. Circ Heart Fail. (2015) 8:261–7. doi: 10.1161/CIRCHEARTFAILURE.114.001542

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am. J. Med. (2011) 124:136–43. doi: 10.1016/j.amjmed.2010.08.017

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Skalska A, Wizner B, Wiêcek A, Zdrojewski T, Chudek J, Klich-Ręczka A, et al. Reduced functionality in everyday activities of patients with self-reported heart failure hospitalization–population-based study results. Int J Cardiol. (2014) 176:423–9. doi: 10.1016/j.ijcard.2014.07.099

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Yokota J, Ryunosuke E, Ren T, Yuko M, Keisuke M. Dysphagia and malnutrition limit activities of daily living improvement in phase i cardiac rehabilitation: a prospective cohort study for acute phase heart failure patients. Heart Vessels. (2021) 36:1306–16. doi: 10.1007/s00380-021-01814-1

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Manemann SM, Chamberlain AM, Roger VL, Boyd C, Cheville A, Dunlay SM, et al. Multimorbidity and functional limitation in individuals with heart failure: a prospective community study. J Am Geriatr Soc. (2018) 66:1101–7. doi: 10.1111/jgs.15336

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Murad K, Goff DCJ, Morgan TM, Burke GL, Bartz TM, Kizer JR, et al. Burden of comorbidities and functional and cognitive impairments in elderly patients at the initial diagnosis of heart failure and their impact on total mortality: the cardiovascular health study. JACC Heart Fail. (2015) 3:542–50. doi: 10.1016/j.jchf.2015.03.004

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Gure TR, Kabeto MU, Blaum CS, Langa KM. Degree of disability and patterns of caregiving among older Americans with congestive heart failure. J. Gen Intern Med. (2008) 23:70–6. doi: 10.1007/s11606-007-0456-1

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Vaccarino V, Kasl SV, Abramson J, Krumholz HM. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol. (2001) 38:199–205.

Google Scholar

17. Kanda M, Tateishi K, Nakagomi A, Iwahana T, Okada S, Kuwabara H, et al. Association between early intensive care or coronary care unit admission and post-discharge performance of activities of daily living in patients with acute decompensated heart failure. PLoS One. (2021) 16:e251505. doi: 10.1371/journal.pone.0251505

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Chivite D, Formiga F, Corbella X, Conde-Martel A, Aramburu Ó, Carrera M, et al. Basal functional status predicts one-year mortality after a heart failure hospitalization in elderly patients – the RICA prospective study. Int J Cardiol. (2018) 254:182–8. doi: 10.1016/j.ijcard.2017.10.104

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Rodríguez-Pascual C, Vilches-Moraga A, Paredes-Galán E, Ferrero-Marinez AI, Torrente-Carballido M, Rodríguez-Artalejo F Comprehensive geriatric assessment and hospital mortality among older adults with decompensated heart failure. Am Heart J. (2012) 164:756–62. doi: 10.1016/j.ahj.2012.08.009

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H Chart-2 Investigators. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan–first report from the CHART-2 study. Circ J. (2011) 75:823–33. doi: 10.1253/circj.cj-11-0135

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. (2014) 63:1123–33. doi: 10.1016/j.jacc.2013.11.053

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Rajadurai J, Tse H, Wang C, Yang NI, Zhou J, Sim D. Understanding the epidemiology of heart failure to improve management practices: an Asia-pacific perspective. J Card Fail. (2017) 23:327–39. doi: 10.1016/j.cardfail.2017.01.004

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Reyes EB, Ha JW, Firdaus I, Ghazi AM, Phrommintikul A, Sim D, et al. Heart failure across Asia: same healthcare burden but differences in organization of care. Int J Cardiol. (2016) 223:163–7. doi: 10.1016/j.ijcard.2016.07.256

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Bozkurt B, Fonarow GC, Goldberg LR, Guglin M, Josephson RA, Forman DE, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. (2021) 77:1454–69. doi: 10.1016/j.jacc.2021.01.030

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Zwisler A, Norton RJ, Dean SG, Dalal H, Tang LH, Wingham J, et al. Home-based cardiac rehabilitation for people with heart failure: a systematic review and meta-analysis. Int J Cardiol. (2016) 221:963–9. doi: 10.1016/j.ijcard.2016.06.207

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Meng Y, Zhuge W, Huang H, Zhang T, Ge X. The effects of early exercise on cardiac rehabilitation-related outcome in acute heart failure patients: a systematic review and meta-analysis. Int J Nurs Stud. (2022) 130:104237. doi: 10.1016/j.ijnurstu.2022.104237

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Turk-Adawi K, Supervia M, Lopez-Jimenez F, Pesah E, Ding R, Britto RR, et al. Cardiac rehabilitation availability and density around the globe. EClinicalMedicine. (2019) 13:31–45. doi: 10.1016/j.eclinm.2019.06.007

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Mathews L, Brewer LC. A review of disparities in cardiac rehabilitation: EVIDENCE, DRIVERS, AND SOLUTIONS. J Cardiopulm Rehabil. (2021) 41:375–82. doi: 10.1097/HCR.0000000000000659

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Turk-Adawi K, Sarrafzadegan N, Grace SL. Global availability of cardiac rehabilitation. Nat Rev Cardiol. (2014) 11:586–96. doi: 10.1038/nrcardio.2014.98

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Gravely S, Tamim H, Smith J, Daly T, Grace SL. Non-symptom-related factors contributing to delay in seeking medical care by patients with heart failure: a narrative review. J Card Fail. (2011) 17:779–87. doi: 10.1016/j.cardfail.2011.05.003

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J. Cardiol. (2011) 57:131–40. doi: 10.1016/j.jjcc.2011.01.002

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Tamamura Y, Matsuura M, Shiba S, Nishikimi T. Heart failure assessed based on plasma B-type natriuretic peptide (BNP) levels negatively impacts activity of daily living in patients with hip fracture. PLoS One. (2020) 15:e237387. doi: 10.1371/journal.pone.0237387

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Leszek P, Waś D, Bartolik K, Witczak K, Kleinork A, Maruszewski B, et al. Burden of hospitalizations in newly diagnosed heart failure patients in Poland: real world population based study in years 2013-2019. ESC Heart Fail. (2022) 9:1553–63. doi: 10.1002/ehf2.13900

PubMed Abstract | CrossRef Full Text | Google Scholar